Is the price fair?
What ELAN's price assumes
Elanco Animal Health Incorporated did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 2.47× revenue.
2.47
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 3.1%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.5%
- Growth the price implies
- +12%
Growth the price implies · The price pays for +12% free cash flow growth a year for a decade; revenue has grown +5.1% a year over the last three.
- Price / book
- 1.86
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 1.86
- EV / sales2026-Q1
- 3.15
- Free cash flow, trailing twelve months
- $379M
- Market capitalisation
- $12.1B
- 3-year revenue growth
- +5.1%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #1 of 28 by Smart Score